Meeting
2023 ASCO Annual Meeting
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.
Authors
Ye Wang
Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Shanghai, Shanghai/China, China
Ye Wang , Duancheng Guo , Zhonghua Tao , Xichun Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1085)
DOI
10.1200/JCO.2023.41.16_suppl.1085
Abstract #
1085
Poster Bd #
306
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Molecular characterization of luminal breast tumors in African American women.
First Author: Yael Simons
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome.
First Author: Qiang Zhang
Poster
2024 ASCO Annual Meeting
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
First Author: Rachel Occhiogrosso Abelman
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi